A5075458052- Chronic Lymphocytic Leukemia Research
- Venous Thromboembolism Diagnosis and Management
- Advanced Breast Cancer Therapies
- Mechanical Circulatory Support Devices
- Lymphoma Diagnosis and Treatment
- Hemophilia Treatment and Research
- Reproductive Health and Contraception
- Silkworms and Sericulture Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- COVID-19 Impact on Reproduction
- Diabetes Treatment and Management
- Platelet Disorders and Treatments
- Heart Failure Treatment and Management
- Inflammatory Biomarkers in Disease Prognosis
- Agriculture and Biological Studies
- Blood Coagulation and Thrombosis Mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- COVID-19 Clinical Research Studies
- HER2/EGFR in Cancer Research
- Erythropoietin and Anemia Treatment
- Statistical Methods in Clinical Trials
- Transplantation: Methods and Outcomes
- Organ and Tissue Transplantation Research
- Cardiac tumors and thrombi
Rockefeller University
2024
Presbyterian Hospital
2024
Cornell University
2022-2024
Oregon Health & Science University
2020-2023
Hudson Institute
2023
NewYork–Presbyterian Hospital
2022
Venous thromboses are well-established complications of hormonal therapy. Thrombosis risk is seen with both contraceptive agents and hormone replacement therapy for menopause gender transition. Over the past several decades, large epidemiological studies have helped better define these risks.
Abstract Background Cyclin-dependent kinase 4/6 inhibitors (CDKi) have changed the landscape for treatment of patients with hormone receptor positive, human epidermal growth factor 2-negative (HR+/HER−) metastatic breast cancer (MBC). However, next-line strategies after CDKi progression are not yet optimized. We report here impact clinical and genomic factors on post-CDKi outcomes in a single institution cohort HR+/HER2− MBC. Methods retrospectively reviewed medical records MBC that received...
Abstract Objectives We aimed to evaluate thrombotic and hemorrhagic complications with heparin versus bivalirudin use in veno‐venous extracorporeal membrane oxygenation (V‐V ECMO). Methods performed a retrospective cohort study of adult patients placed on V‐V ECMO intravenous anticoagulation either or bivalirudin. Time event major bleed were analyzed addition related outcomes. Results identified 95 ECMO: 61 receiving heparin, 34 The group had higher rate severe COVID‐19, BMI, longer...
Platelet clot retraction, the ultimate phase of platelet thrombus formation, is critical for stabilization. It requires functional αIIbβ3 receptors, fibrin, and integrated actions actin-myosin contractile cytoskeletal systems. Disturbances in retraction have been associated with both bleeding thrombosis. We recently demonstrated that platelets treated antagonist peptide RGDW, which eliminates fibrinogen-mediated aggregation, are still able to retract clots. exploited this observation...
Abstract Objective Estrogen‐containing contraceptives and hormone replacement therapy are used commonly, however, the risks of venous arterial thrombosis imparted by such medications during COVID‐19 infection or other similar viral infections remain undescribed. Methods To assess risk in patients receiving oral estrogen‐containing (ECT) with as compared to those non‐estrogen‐based hormonal therapy, we conducted a multicenter cohort study 991 confirmed infection, 466 525 progestin‐only...
OBJECTIVES/GOALS: The research objectives of this project are to elucidate the effects Bruton’s tyrosine kinase inhibitors (BTKi) varying target specificity on platelet function with regard aggregation, adhesion, spreading, and intracellular signaling as measured by phosphorylation. METHODS/STUDY POPULATION: Blood from healthy volunteers was obtained processed obtain both washed platelets platelet-rich plasma. samples were then treated one BTKi drugs or vehicle (DMSO) at concentrations...
Abstract Patients with acquired haemophilia A (PwAHA) can present severe bleeding and may require lengthy treatment bypassing agents immunosuppression. We two cases of the implementation emicizumab in PwAHA. The first patient, an 82-year-old man rheumatoid arthritis (RA), presented (AHA) spontaneous left tibia hematoma complicated by a persistent wound infections. After month intermittent at site immunosuppression, inhibitor level remained elevated he was placed on emicizumab. While therapy,...
e13030 Background: CDKi with endocrine therapy (ET) is approved treatment of metastatic HR+/HER2- breast cancer based on PFS benefit vs ET alone. Outcomes data following discontinuation (dc) limited, trials ongoing in this setting. The reported phenomenon rapid progression within 4 months dc raises concern over impact MBC biology. This study aims to define outcomes after and identify predictors progression. Methods: a retrospective review women ≥18 years who received between 4/1/14 12/1/19....
Introduction: Extracorporeal membrane oxygenation (ECMO) is associated with significant thrombotic complications necessitating anticoagulation, though optimal strategy remains unknown. We aimed to evaluate and hemorrhagic heparin versus bivalirudin use in veno-venous (V-V) ECMO.Methods: performed a retrospective cohort study of adult patients placed on V-V ECMO intravenous anticoagulation either or bivalirudin. Time event (patient-sided thrombus circuit lung exchange) major bleed were...